Chemomab Therapeutics Investor Relations Material
Latest events
Study Result
Chemomab Therapeutics
Q1 2025
15 May, 2025
Q4 2024
3 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Chemomab Therapeutics Ltd
Access all reports
Chemomab Therapeutics Ltd is an Israel-based clinical-stage biotechnology company focused on the development of therapies for fibrotic and inflammatory diseases. The company’s lead drug candidate is based on targeting CCL24, a chemokine involved in fibrosis and inflammation. Chemomab's pipeline includes treatments for conditions such as primary sclerosing cholangitis (PSC) and systemic sclerosis. The company conducts preclinical and clinical studies and collaborates with research institutions to advance its drug development efforts. Chemomab Therapeutics Ltd is headquartered in Tel Aviv, Israel, and its shares are listed on the NASDAQ.
)
)
)